Introduction: The gain-of-function mutations that underlie sodium channel myotonia (SCM) and paramyotonia congenital (PMC) produce differing clinical phenotypes. We used muscle velocity recovery cycles (MVRCs) to investigate membrane properties. Methods: MVRCs and responses to trains of stimuli were compared in patients with SCM (n 5 9), PMC (n 5 8), and normal controls (n 5 26). Results: The muscle relative refractory period was reduced in SCM, consistent with faster recovery of the mutant sodium channels from inactivation. Both SCM and PMC showed an increased early supernormality and increased mean supernormality following multiple conditioning stimuli, consistent with slowed sodium channel inactivation. Trains of fast impulses caused a loss of amplitude in PMC, after which only half of the muscle fibers recovered, suggesting that the remainder stayed depolarized by persistent sodium currents. Discussion: The differing effects of mutations on sodium channel function can be demonstrated in human subjects in vivo using this technique. 57: 586-594, 2018 Mutations in the transient sodium channel Nav1.4 underlie both sodium channel myotonia (SCM) and paramyotonia congenita (PMC). Patients with SCM typically have myotonic stiffness following muscle contraction, which improves with repetition (the "warm-up" phenomenon) and do not have exercise-induced or cold-induced weakness. These patients may sometimes demonstrate mild worsening of stiffness with repeated muscle contraction (paradoxical myotonia), particularly with forced eye closure, before subsequently showing the typical warm-up phenomenon.
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Patients with PMC typically have paradoxical myotonia as well as exercise-related weakness, particularly with muscle exertion at cold temperatures. With warming, this weakness does not resolve immediately and, when severe, may take several hours to recover. Some patients may also have exercise-induced weakness at room temperature.
The sodium channel mutations in both conditions produce a gain-of-function abnormality resulting from disrupted inactivation or enhanced activation. Slowed fast inactivation increases the action potential duration, which increases the potassium efflux into the t-tubules, resulting in a larger after depolarization following each action potential, which, when sufficient, triggers spontaneous action potentials leading to a train of myotonic discharges. 1 In some PMC mutations, there is often an additional problem disrupting the final extent of inactivation as well as a cold-induced left shift of the activation curve causing a greater and more persistent inward sodium current, leading to more marked depolarization and consequent weakness. 2 It would be helpful if these membrane abnormalities could be reliably studied in vivo, particularly as a potential tool for assessing the efficacy of any treatment interventions. A convenient but necessarily indirect method of inferring changes in muscle fiber membrane properties in vivo is to measure how the velocity of a muscle action potential depends on the time interval after a preceding action potential, the muscle velocity recovery cycle (MVRC). 3 Immediately after an action potential the muscle fiber is refractory, and then during the muscle relative refractory period (MRRP), a second impulse is conducted more slowly. Following the MRRP, there is a supernormal period, when action potentials are conducted faster than normal, which lasts at least 1 s. The supernormal period comprises 2 functional components: early supernormality (ESN), which is related to an early depolarizing afterpotential, and late supernormality (LSN), which is related to a late depolarizing afterpotential and, unlike ESN, is increased by multiple conditioning impulses. Like superexcitability in nerve, ESN in muscle is strongly dependent on membrane potential and sodium channel gating because they depend primarily on the excess of inward sodium charge movement over outward potassium charge movement during the action potential. LSN has no equivalent in nerve and is thought to relate to potassium accumulation in the t-tubule system. 3 MVRCs, consisting of MRRP, ESN and LSN, can be reliably measured in human muscles by direct stimulation and recording of a bundle of adjacent muscle fibers with a sequence of paired electrical pulses of equal amplitude and varying interstimulus interval (ISI). [3] [4] [5] They indicate a rapid onset of membrane depolarization during limb ischemia 3 and have been used to infer muscle membrane depolarization in renal failure 6 and to provide information about membrane abnormalities in critical illness myopathy, 7 Andersen-Tawil syndrome, 8 myotonia congenital (MC), 9 and myotonic dystrophy. 10 This study uses MVRCs, supplemented by 2 previously described repetitive stimulation protocols, 11 to investigate the muscle membrane abnormalities in SCM and PMC. We seek to determine whether these new methods can provide new insights into the pathophysiology of these sodium channelopathies or provide new measures that could be useful as biomarkers.
MATERIALS AND METHODS
Patients. There were 9 patients with SCM and 8 patients with PMC (Table 1 ). The patients with SCM were 45.6 6 13.6 years of age (mean 6 SD, range 22-67), and the patients with PMC were 46.8 6 18.4 years of age (range 21-72). All were genetically confirmed. The patients with PMC all had the same common Thr1313Met mutation, and 5 of the patients with SCM had the Val1589Met mutation.
Asymptomatic Controls. The MVRC studies were compared with recordings from 26 healthy volunteers (10 men, 16 women) 44.2 6 12.3 years of age (range 27-66) who served as normal controls (NCs).
Consent. Informed written consent was obtained from all patients and controls according to the Declaration of Helsinki. This study was approved by the St Thomas' Hospital research ethics committee.
Study Protocol. Standard nerve conduction studies, muscle velocity recovery studies, and the short exercise test at room temperature were conducted for all patients, and a blood sample for electrolytes and glucose taken on the same day.
Short Exercise Test. Short exercise tests (SETs) were performed by stimulating the ulnar nerve at the wrist and recording with surface electrodes over the abductor digiti minimi. Compound muscle action potentials were recorded at baseline and every 10 s during 3 short exercise trials (10 s of exercise followed by 60 s of rest). The amplitude changes from baseline were calculated and plotted as described previously. 12 The SET pattern was given a number as described by Fournier and colleagues 13 : pattern 1, decrement without recovery during the 60-s rest period, typically worsening with consecutive exercise trials; pattern 2, transient decrement with recovery during each 60-s rest period, often becoming less marked with subsequent exercise trials; pattern 3, no decrement.
Muscle Velocity Recordings.
Experimental Setup. The recording technique was performed as described previously for tibialis anterior (TA) [8] [9] [10] and is briefly summarized below. For details of the MVRC and ramp protocols see Tan et al. 2014 , 9 and for details of the repetitive stimulation protocol see Tan et al. 2012. 8 Recordings were performed from the distal third of TA. Stimuli consisting of 0.05-ms rectangular current pulses were delivered through an insulated monopolar needle electrode with a surface electrode as anode. Muscle activity was recorded with a concentric needle electrode approximately 20 mm proximal to the stimulating needle. Patients were studied in a heated room and kept warm in an effort to achieve a skin temperature as near as possible to 32 8C at the start of the study. Surface temperature over TA was recorded at the end of the recording.
The signal was amplified (gain 300-1,000, bandwidth 0.2 HZ to 3 kHZ) and digitized (NIDAQ-6062E; National Instruments Europe Corp, Debrecen, Hungary) by using a sampling rate of 20 kHZ. The needle electrodes were adjusted to obtain a stable negative peak response with a stimulus of 3-10 mA. Stimulation and recording were controlled by Qtrac software (Digitimer Ltd, Welwyn Garden City, United Kingdom) with the 1200RCMQ.QRP recording protocol.
MVRCs at Rest. MVRCs were recorded following 1, 2, and 5 conditioning stimuli (10 ms apart). Test stimuli were delivered every 2 s. The ISI between the last conditioning stimulus and the test stimulus was reduced from 1,000 to 1.4 ms in 34 steps in an approximately geometric series.
Frequency Ramp. To characterize the effects of progressive muscle activation, a 1-s train of stimuli was delivered every 2 sec, with the number of stimuli in the train increased (ramped up in frequency) by 1 from 2 to 31 in successive 2-s cycles. 11 During the frequency ramp, the mean stimulation rate increased from 1 to 15.5 HZ over 1 min, and responses were measured to the first and last stimuli in each train. Stimulus cycles with the test stimulus alone were recorded before the frequency ramp (10 cycles at 0.5 HZ) and for 30 s after the end of the ramp (15 cycles at 0.5 HZ).
Repetitive Stimulation. The effects of intermittent high-frequency electrical stimulation on muscle membrane properties were studied by recording repeated short (18-step) MVRCs and then interleaving the conditioning and test stimuli with 1-s trains of stimuli at 20 HZ, as previously described in detail. 8, 11 Four MVRCs were initially recorded at rest (each providing estimates of MRRP and ESN), and then 5 MVRCs were measured during intermittent 20-HZ stimulation for 6 min; further MVRCs were recorded during recovery for at least 5 min.
Data Analysis. Recovery cycle data were analyzed by the QtracP program, as previously described. 3, 4 After filtering the responses, latencies were measured from the start of the test stimulus to the negative peak of the muscle action potential. The effects of 1, 2, and 5 conditioning pulses on the latency of the test response were calculated as percentage differences compared with the responses to the test stimulus alone. Excitability measures were derived from the 3 recording protocols.
MVRCs at rest. The MRRP was defined as the earliest (interpolated) ISI at which the latencies of the conditioned and unconditioned test responses were identical. ESN was measured as the largest percentage decrease in latency for ISIs below 15 ms. LSN was the mean percentage decrease in latency for ISIs between 50 and 150 ms. We defined supernormality at 20 ms as the mean of supernormalities at 18 and 22 ms, 5ESN as the early supernormality after 5 conditioning impulses, and residual supernormality (RSN) as the mean percentage decrease in latency at the end of the sweep, averaged for ISIs of 900 and 1,000 ms. Mean supernormality (MSN) is the average latency reduction between RRP and 1 s, corresponding to area under curve when plotted with linear ISI axis. We also defined the "extra" supernormalities 5XLSN, 5XMSN, and 5XRSN as the differences between the percentage latency decreases for 5 and 1 conditioning stimuli. Supernormality to 5 conditioning stimuli at 20 ms was defined as the mean of supernormalities at 18 and 22 ms to 5 conditioning stimuli.
In our earlier study of patients with MC, we found that those receiving mexiletine were distinguished by having significantly smaller values of 5ESN. 9 To determine whether inclusion of these patients was materially affecting the results, we compared 5ESN values inclusive and exclusive of these patients. Repetitive stimulation. The MVRC measurements taken during intermittent 20-HZ stimulation were changes in peak amplitude and latency, MRRP, and ESN. These values were averaged for the first 2 (1,2) and the last 2 (4,5) cycles of intermittent 20-HZ stimulation and for cycles 1-3 during recovery after the end of repetitive stimulation.
Statistical Analysis. We used the Welch rank test (nonparametric unequal variance t test) for intergroup comparisons. When comparing groups with multiple comparisons or correlations, only P < 0.01 was considered significant, but, for discussion, P < 0.05 is mentioned when relevant for individual tests.
RESULTS
Nerve Conduction Studies. No patients had evidence of a generalised large-fiber neuropathy.
Short Exercise Test. The results of the SETs at room temperature are detailed in Table 1 . The SET performed on the day of the muscle excitability studies showed a progressive decrement typical of PMC (pattern 1) in 6 of 8 patients with PMC. Two patients with SCM showed a fluctuating decrement which did not correspond to patterns 1 or 2. The remaining patients showed no abnormal decrement (pattern 3).
Velocity Recovery Cycles. The results of the MVRCs with 1, 2 and 5 conditioning stimuli are illustrated in Figure 1 , and the measurements are compared in Table 2 . The most striking feature, which is common to both SCM and PCM patients, is an increase in supernormality that becomes more pronounced and prolonged by additional conditioning stimuli so that, with 5 conditioning stimuli, there are highly significant increases, compared with controls, in early supernormality (5ESN) and also in the extra late supernormality (5XLSN) and extra mean supernormality over 1 s (5XMSN) compared with a single conditioning impulse. The differences between SCM and PMC, on the one hand, and MC, on the other hand, were most marked in the case of the extra residual supernormality at 900-1,000 ms (5XRSN: NC 5 1.0%, SCM and PMC 5 1.7%, MC 5 2.8%).
The main difference between the recovery cycles of SCM and PMC patients was in their relative refractory period (MRRP) and time to peak supernormality (ISI for maximum ESN [ESN@)]. In this respect, the patients with SCM showed a significantly quicker postspike recovery of excitability compared with the controls or the PMC patients.
In this study, only 1 patient with SMC and 1 patient with PMC were under the influence of mexiletine at the time of the recordings. In both cases, 5ESN values for the patient on mexiletine were actually above the average of the others, and mean values were not appreciably affected: SMC 16.9 including mexiletine and 16.7 excluding mexiletine; PMC 15.5 including mexiletine and 15.2 excluding mexiletine; all values well above 13.0 for the normal controls. Because of the limited number of patients and the absence of any clear effect of mexiletine, the 2 patients on mexiletine were included in the remaining analyses.
Frequency Ramp. The results of increasing the stimulation rate up to an average of 15.5 HZ by adding intermittent 1-s trains of conditioning stimuli at frequencies from 1 to 30 HZ are illustrated for a patient with SCM in Figure 2A and for a patient with PMC in Figure 2B . The average changes in latency and peak amplitude compared with the normal control subjects is illustrated in Figure 3 and Table 3 .
This stimulation protocol produced only modest changes in amplitude for the patients with SCM, just as for the controls (Figs. 2A, 3 ). In contrast, there were marked changes in the PMC group, in all of whom the amplitude of the responses dropped during the ramp and only partially recovered afterward, as shown in Figures 2B  and 3 . Because of the almost complete loss of amplitude during the high-frequency trains, it was not possible to measure latencies for most of the patients with PMC for the last action potential in each train for the latter part of the frequency ramp. There was, however, always some recovery by the time the next train started 1 s later, so latencies for the first action potential in each train were always measurable.
In the SCM group, the main difference compared with the controls was a greater reduction in latency at 15 HZ, especially at the end of the 15- HZ train, indicating a greater than normal depolarization.
Repetitive Stimulation. The results of interspersing a 1-s train of 20 stimuli between recovery cycle measurements for a period of 6 min are illustrated in Figure 4 , and measurements are listed in Table  4 . As with the frequency ramp, the most conspicuous abnormality was seen in the responses of the patients with PMC, who suffered a severe loss of amplitude when the 20-HZ trains were started, which made the latencies of many of the subsequent responses unmeasurable.
In the SMC group, the abnormally short RRPs and high ESN values were maintained throughout the period of repetitive stimulation. The most distinctive feature was a failure to show the normal decrease in supernormality during the repetitive stimulation so that the most significant abnormality in our recordings from these patients was the value of ESN during cycles 4 and 5.
Separation of Myotonia Subtypes. Supporting Information Figure 1 explores the potential use of the various MVRC and other measurements to distinguish between the different types of myotonia studied so far. Supporting Information Figure 1A shows that the drop in amplitude of the muscle action potentials during the frequency ramp separates the PMC patient from the other groups, including the previously studied 11 MC patients that were not taking medication. 9 Combinations of MVRC and frequency ramp measurements provided separation between the 3 myotonia subtypes (Supp. Info. Fig.  1B ) or between PMC, MC, and normal controls (Supp. Info. Fig. 1C) . In most measurements, there was considerable overlap between the SMC and NC groups, and combinations of MVRC, frequency ramp, and repetitive stimulation measurements were required to separate them (Supp. Info. Fig. 1D ).
DISCUSSION

Conduction Changes Related to Myotonia and
Weakness. We have previously reported that in MC the lack of functional chloride channels results in increased early, late, and residual supernormality, indicating an enhanced depolarizing afterpotential that increases and becomes prolonged with trains of impulses. 9 These changes are in the direction expected to facilitate repetitive myotonic discharges, although such activity was not detected in the small columns of muscle fibers studied. Rather, similar increases in early, late, and residual supernormality were seen in both the SCM and PMC groups of patients. Although less pronounced than in MC (e.g., 5XLSN: NC 5 7.0%, SCM and PMC 5 9.1%, MC 5 10.1%; 5XMSN: NC 5 3.5%, SCM and PMC 5 4.4%, MC 5 5.8% ), it seems reasonable to conclude that the enhanced depolarizing afterpotentials that give rise to the supernormality provide the trigger for myotonia in these patients also.
Because MRRP and ESN@ are strongly temperature dependent, it is important to note that the skin temperatures recorded in the patients with SCM (30.2 8C 6 0.4 8C, mean 6 SE) were no warmer than those in the controls (30.4 8C 6 0.2 8C) or in the patients with PMC (30.6 8C 6 0.7 8C).
In our previous study with MC patients, 9 mexiletine was associated with a reduced 5ESN. In this study, the SCM and PMC patients on mexiletine each had 5ESN values above the average in their respective groups. One possible explanation for the difference being in the opposite direction to that expected compared with the patients not on mexiletine is that the 2 patients taking regular mexiletine were particularly clinically symptomatic, and it is possible that their symptoms reflected the degree of channel dysfunction and, therefore, even treatment with mexiletine did not result in reduction of the 5ESN below the mean for the rest of the group.
Weakness is a feature of PMC but not of SCM. Whereas very little difference is seen between these 2 groups in the effects of 1-5 conditioning stimuli, the biophysical basis for the weakness in PMC is clearly seen in the effects of the frequency ramp and repetitive stimulation in Figures 2-4 . In all 8 patients, there was a similar rapid decline in amplitude of the muscle action potentials at frequencies above about 10 HZ. The lack of full recovery in the amplitude after the end of the ramp accounts for the weakness that can continue in patients with PMC after exercise. Given that the latency returned to normal, it appears that the population of muscle fibers was split by the frequency ramp; about half of the fibers recovered to normal resting potential, whereas the remainder stayed sufficiently depolarized to be inexcitable. This bistability of the membrane potential can be explained by the sodium channel mutation, as discussed below. Unlike the SET at room temperature, in which 2 of the 8 PMC patients failed to show an abnormality, the frequency ramp demonstrated a clear abnormality in all 8 of these patients, as did the later intermittent stimulation at 20 HZ.
Relationship of Conduction Changes to Sodium
Channel Mutations. The larger ESN, indicating an increased depolarizing afterpotential, in both SCM and PMC groups is consistent with a lengthened duration of the muscle action potential due to a slower rate of entry into inactivation (SCM and PMC) and slowed deactivation in SCM. [14] [15] [16] In spite of this, the relative refractory period (MRRP) was significantly shorter than normal in the SCM group. This can be explained by the faster recovery of the mutant sodium channel from inactivation, which has been found for Val1589Met mutations (the most common among our patients with SCM) expressed in human embryonic kidney cells in vitro. 17 For patients with PMC, their Thr1313Met mutation has been reported to induce both slowed inactivation 18 and faster recovery from inactivation, 16 and these effects appear largely to cancel out.
The most striking difference between the SCM and PMC mutations was in their effects on repetitive stimulation in the frequency ramp. At high frequencies, the PMC muscle fibers became depolarized to inexcitability, and, after the train, only about half the fibers recovered their membrane potential, as discussed above. In the fibers that remained depolarized, a continuous source of depolarizing current, sufficient to outweigh the repolarizing potassium and chloride currents, was presumably provided by the mutant sodium channels. Consistent with this, all the patients with PMC in this study had the Thr1313Met mutation, which has been shown by in vitro heterologous expression experiments to generate unusually large persistent (noninactivating) sodium currents. 16 The persistent sodium currents are regenerative and allow the muscle fibers to exist in 2 stable states, either at a normal resting potential with the currents switched off or held depolarized and inexcitable by strongly activated persistent currents. It seems that the muscle fibers that recovered from the frequency ramp protocol were not inherently resistant to this regenerative depolarization because, when they were subjected to a further bout of repetitive stimulation with the intermittent 20-HZ protocol (which always followed the frequency ramp), there was a further substantial drop in amplitude, which was again irreversible for the duration of the experiment (Fig. 4C) .
In conclusion, although it is of interest that multiple measurements are able to separate different myotonia subtypes, we do not advocate the use of these techniques as a diagnostic utility. Muscle channelopathy gene panels have increasingly become more widely available and affordable, and there is a decreasing requirement for electrodiagnostic guides to genetic testing. Instead, the strength of these techniques is in providing a means of studying the effects of the muscle ion channel mutations in vivo. This study has shown that abnormalities in mutant sodium channel function can be demonstrated in vivo in human subjects by using muscle excitability studies. In earlier publications [8] [9] [10] we have shown that alterations in chloride and potassium channel function are also demonstrable using this stimulation paradigm. The method is minimally invasive (the stimulation setup is similar to stimulated single-fiber electromyography studies), relatively painless, and can be easily repeated in the same individual over time. It is therefore suitable for use as a biomarker in future treatment trials.
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